Pharma News

Celltrion’s Vegzelma (bevacizumab-adcd) has received FDA’s approval for treatment of metastatic colorectal cancer; recurrent or metastatic non-squamous nonsmall-cell lung cancer (nsNSCLC); recu...

Shionogi said that its investigational COVID-19 treatment ensitrelvir fumaric acid has shown promising results in a phase 3 clinical trial.

CRISPR Therapeutics has received a Regenerative Medicine Advanced Therapy designation from the FDA for its CTX130 for treatment of patients with either of two types of cutaneous T-cell lymphoma —...

Enalare Therapeutics has secured a contract from the Biomedical Advanced Research and Development Authority (BARDA) worth up to $50.3 million for its investigational respiratory stimulant ENA-001. ...

The FDA has granted a Priority Review to Pharming’s New Drug Application (NDA) for leniolisib to treat patients with activated phosphoinositide 3-kinase delta syndrome (APDS) who are 12 years an...

For the second time in 15 months, Japanese ophthalmology specialist Santen has earned an FDA approval for its eye drops.

Ayala Pharmaceuticals’ AL102 has gained Fast Track designation for the treatment of progressing desmoid tumors, which don’t metastasize but often aggressively infiltrate neurovascular structure...

NMD Pharma has received FDA’s Orphan Drug designation for its NMD670 candidate for treatment of myasthenia gravis.

Long ignored, dipole-dipole interactions give life its shape.

The European Medicines Agency (EMA) reported that Boehringer Ingelheim’s Actilyse (alteplase), Actilyse Cathlo (alteplase) and Metalyse (tenecteplase) are in short supply. ...

Pfizer and BioNTech have completed an Emergency Use Authorization (EUA) submission for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children between the ages of five and 11. ...

AstraZeneca and Merck have withdrawn Lynparza (olaparib) for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated ovarian cancer who have been treated wit...